Eiger BioPharmaceuticals, Inc.
EIGR
Classifica tra le azioni
#36457
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Prezzo delle azioni
$1.73
Ultima sincronizzazione: 2025-06-17
Capitalizzazione di mercato
$2.55M
Variazione (1 giorno)
-0.29%
Variazione (1 anno)
-79.71%
Paese
US
Scambia Eiger BioPharmaceuticals, Inc. (EIGR)
Categoria
Healthcare
EPS per Eiger BioPharmaceuticals, Inc. (EIGR)
EPS al December 2023 TTM: $-50.79
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Eiger BioPharmaceuticals, Inc., l’EPS attuale della società (TTM) è $-50.79. Alla fine del 2022, la società aveva un EPS di $-69.74 un aumento rispetto a rispetto a quello del 2021, che era di $-29.98.
Storico EPS per Eiger BioPharmaceuticals, Inc. da 2016 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
